Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003)[1].
Molecular Weight:
(144.56 kDa)
Purity:
98.40
CAS Number:
[2556646-63-8]
Target:
PD-1/PD-L1,TGF-beta/Smad
Application Notes:
Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted